Larimar Therapeutics (LRMR) Stock Forecast & Price Target

Compare

859 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LRMR Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Larimar

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LRMR Stock 12 Month Forecast

Average Price Target

$19.75

▲(401.27% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Larimar Therapeutics in the last 3 months. The average price target is $19.75 with a high forecast of $33.00 and a low forecast of $10.00. The average price target represents a 401.27% change from the last price of $3.94.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","34":"$34","9.25":"$9.25","17.5":"$17.5","25.75":"$25.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,9.25,17.5,25.75,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,5.713846153846154,7.987692307692308,10.26153846153846,12.535384615384615,14.80923076923077,17.083076923076923,19.356923076923078,21.630769230769232,23.904615384615386,26.17846153846154,28.452307692307695,30.726153846153846,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,4.694615384615385,5.949230769230769,7.203846153846154,8.458461538461538,9.713076923076922,10.967692307692307,12.222307692307691,13.476923076923075,14.73153846153846,15.986153846153844,17.240769230769228,18.495384615384616,{"y":19.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,3.9446153846153846,4.44923076923077,4.953846153846154,5.458461538461538,5.963076923076923,6.4676923076923085,6.972307692307693,7.476923076923077,7.981538461538461,8.486153846153847,8.990769230769232,9.495384615384616,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$33.00

Average Price Target$19.75

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Myles Minter

William Blair

―

Buy

―

Reiterated

08/29/25

Promising Developments and Strategic Timeline Drive Buy Rating for Larimar Therapeutics

Yatin Suneja

Guggenheim

$26

Buy

559.90%

Upside

Reiterated

08/19/25

Guggenheim Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)

Jonathan Wolleben

Citizens JMP

$18

Buy

356.85%

Upside

Reiterated

08/19/25

Larimar Therapeutics (LRMR) Gets a Buy from Citizens JMP

Joori Park

Leerink Partners

―

Buy

―

Reiterated

08/19/25

Positive Outlook for Larimar Therapeutics: Buy Rating Supported by FDA Decisions and Upcoming Trial Data

Samantha Semenkow

Citi

$12

Buy

204.57%

Upside

Reiterated

08/19/25

Buy Rating for Larimar Therapeutics: Strong Phase 3 Progress, Regulatory Alignment, and Market Advantage

Andreas Argyrides

Oppenheimer

$26

Buy

559.90%

Upside

Reiterated

08/18/25

On 8/14, Larimar (LRMR) announced 2Q25 financials and provided a business update. We reiterate Outperform.

Joon Lee

Truist Financial

$18

Buy

356.85%

Upside

Reiterated

08/14/25

Larimar Therapeutics (LRMR) Gets a Buy from Truist FinancialTruist Securities analyst Joon Lee reiterated a Buy rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).

Cory Jubinville, PhD

LifeSci Capital

$33

Buy

737.56%

Upside

Reiterated

08/14/25

Promising Advancements and Strategic Positioning Drive Buy Rating for Larimar Therapeutics

Catherine Novack

JonesTrading

$12→$10

Buy

153.81%

Upside

Reiterated

08/04/25

JonesTrading Remains a Buy on Larimar Therapeutics (LRMR)Jones Trading analyst Catherine Novack lowered the price target on Larimar Therapeutics (NASDAQ: LRMR) to $10.00 (from $12.00) while maintaining a Buy rating.

Laura Chico

Wedbush

$17→$15

Buy

280.71%

Upside

Reiterated

06/24/25

Larimar Therapeutics price target lowered to $15 from $17 at WedbushLarimar Therapeutics price target lowered to $15 from $17 at Wedbush

Joel Beatty

Robert W. Baird

$13→$10

Buy

153.81%

Upside

Reiterated

03/25/25

Larimar Therapeutics price target lowered to $10 from $13 at BairdLarimar Therapeutics price target lowered to $10 from $13 at Baird

Edward White

H.C. Wainwright

$15→$16

Buy

306.09%

Upside

Reiterated

03/25/25

Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp's Potential in Treating Friedreich's Ataxia

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Myles Minter

William Blair

―

Buy

―

Reiterated

08/29/25

Promising Developments and Strategic Timeline Drive Buy Rating for Larimar Therapeutics

Yatin Suneja

Guggenheim

$26

Buy

559.90%

Upside

Reiterated

08/19/25

Guggenheim Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)

Jonathan Wolleben

Citizens JMP

$18

Buy

356.85%

Upside

Reiterated

08/19/25

Larimar Therapeutics (LRMR) Gets a Buy from Citizens JMP

Joori Park

Leerink Partners

―

Buy

―

Reiterated

08/19/25

Positive Outlook for Larimar Therapeutics: Buy Rating Supported by FDA Decisions and Upcoming Trial Data

Samantha Semenkow

Citi

$12

Buy

204.57%

Upside

Reiterated

08/19/25

Buy Rating for Larimar Therapeutics: Strong Phase 3 Progress, Regulatory Alignment, and Market Advantage

Andreas Argyrides

Oppenheimer

$26

Buy

559.90%

Upside

Reiterated

08/18/25

On 8/14, Larimar (LRMR) announced 2Q25 financials and provided a business update. We reiterate Outperform.

Joon Lee

Truist Financial

$18

Buy

356.85%

Upside

Reiterated

08/14/25

Larimar Therapeutics (LRMR) Gets a Buy from Truist FinancialTruist Securities analyst Joon Lee reiterated a Buy rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).

Cory Jubinville, PhD

LifeSci Capital

$33

Buy

737.56%

Upside

Reiterated

08/14/25

Promising Advancements and Strategic Positioning Drive Buy Rating for Larimar Therapeutics

Catherine Novack

JonesTrading

$12→$10

Buy

153.81%

Upside

Reiterated

08/04/25

Laura Chico

Wedbush

$17→$15

Buy

280.71%

Upside

Reiterated

06/24/25

Larimar Therapeutics price target lowered to $15 from $17 at WedbushLarimar Therapeutics price target lowered to $15 from $17 at Wedbush

Joel Beatty

Robert W. Baird

$13→$10

Buy

153.81%

Upside

Reiterated

03/25/25

Larimar Therapeutics price target lowered to $10 from $13 at BairdLarimar Therapeutics price target lowered to $10 from $13 at Baird

Edward White

H.C. Wainwright

$15→$16

Buy

306.09%

Upside

Reiterated

03/25/25

Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp's Potential in Treating Friedreich's Ataxia

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Larimar Therapeutics

1 Month

xxx

Success Rate

5/8 ratings generated profit

Average Return

+10.36%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +10.36% per trade.

3 Months

xxx

Success Rate

6/8 ratings generated profit

Average Return

+24.90%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +24.90% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

16/25 ratings generated profit

Average Return

+29.98%

reiterated a buy rating 17 days ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +29.98% per trade.

2 Years

xxx

Success Rate

13/25 ratings generated profit

Average Return

+38.12%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 52.00% of your transactions generating a profit, with an average return of +38.12% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LRMR Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LRMR has received 24 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LRMR average Analyst price target in the past 3 months is 19.75.

Each month's total comprises the sum of three months' worth of ratings.

LRMR Financial Forecast

LRMR Earnings Forecast

Next quarter’s earnings estimate for LRMR is -$0.41 with a range of -$0.50 to -$0.33. The previous quarter’s EPS was -$0.41. LRMR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 47.42% of the time in the same period. In the last calendar year LRMR has Outperformed its overall industry.

No data currently available

LRMR Sales Forecast

Next quarter’s sales forecast for LRMR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. LRMR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.11% of the time in the same period. In the last calendar year LRMR has Preformed in-line its overall industry.

LRMR Stock Forecast FAQ

What is LRMR’s average 12-month price target, according to analysts?

Based on analyst ratings, Larimar Therapeutics, Inc.’s 12-month average price target is 19.75.

What is LRMR’s upside potential, based on the analysts’ average price target?

Larimar Therapeutics, Inc. has 401.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LRMR a Buy, Sell or Hold?

Larimar Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Larimar Therapeutics, Inc.’s price target?

The average price target for Larimar Therapeutics, Inc. is 19.75. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $33.00 ,the lowest forecast is $10.00. The average price target represents 401.27% Increase from the current price of $3.94.

What do analysts say about Larimar Therapeutics, Inc.?

Larimar Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of LRMR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Larimar Therapeutics (LRMR) Stock Forecast & Price Target

LRMR Analyst Ratings

LRMR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Larimar Therapeutics

LRMR Analyst Recommendation Trends

LRMR Financial Forecast

LRMR Earnings Forecast

LRMR Sales Forecast

LRMR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts